The utility of pre-embolization Aspirin administration for ruptured cerebral aneurysms

Pre-surgical Aspirin Administration for Prevention of Thromboembolic Complication of Coil Embolization for Ruptured Cerebral Aneurysms - A-STOP study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031210421

Enrollment

484

Registered

2021-11-11

Start date

2022-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid hemorrahge Subarachnoid hemorrahge

Interventions

[Aspirin group] After the introduction of general anesthesia before embolization, 200 mg of aspirin is administered through the nasogastric tube. [Placebo group] Placebo (lactose) is administered thro

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Ruptured cerebral aneurysm in the acute phase 2) Scheduled for aneurysm embolization within 72 hours of onset 3) Aged 20 years or older at the time of onset 4) Patients who have obtained written informed consent from the patient or his / her surrogate (spouse, parent, adult child, etc.) to participate in this study.

Exclusion criteria

Exclusion criteria: 1) Pre-stroke activity od daily living is not independent (pre-stroke mRS>3) 2) Dissecting cerebral aneurysm who attempted parent artery occlusion 3) Ruptured previously coil embolized cerebral aneurysm 4) Ruptured infectious cerebral aneurysm or i cerebral aneurysm associated with cerebral arteriovenous malformation, moyamoya disease. 5) Patients who are attempted simultaneously to treat two or more aneurysms 6) Having already taken antiplatelet drugs 7) History of allergies to lactose, aspirin, or salicyclic acid based preparations 8) Cannot perform MRI 9) Patinets who had a contraindications to aspirin 10)Doctor in charge deems inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
1) Incidence of intraoperative thrombotic complication 2) Incidence of symptomatic ischemic lesions on MRI-DWI (IRC)	—

Secondary

Measure	Time frame
Important secondary endpoints 1) Incidence of total hemorrhagic events within 14 days from registration 2) Incidence of cerebral ischemic events within 14 days after postoperative MRI imaging Secondary endpoints 1) Incidence of symptomatic ischemic lesions on MRI-DWI (INV) 2) mRS at 3 months Exploratory endpoints 1) Ischemic lesions in MRI-DWI (number and size, IRC or INV) 2) Occurrence rate of intraparenchymal hemorrhage along the tube tract of patients who underwent ventricular drainage on CT within 14 postoperative day	—

Measure

Time frame

Important secondary endpoints 1) Incidence of total hemorrhagic events within 14 days from registration 2) Incidence of cerebral ischemic events within 14 days after postoperative MRI imaging Secondary endpoints 1) Incidence of symptomatic ischemic lesions on MRI-DWI (INV) 2) mRS at 3 months Exploratory endpoints 1) Ischemic lesions in MRI-DWI (number and size, IRC or INV) 2) Occurrence rate of intraparenchymal hemorrhage along the tube tract of patients who underwent ventricular drainage on CT within 14 postoperative day

—

Contacts

Public ContactSakyo Hirai

Institute of Science Tokyo

hirai.evs@tmd.ac.jp+81-3-5803-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026